Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):317-25

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2004 December;48(4):317-25

RADIOIMMUNOTHERAPY
Guest Editor: S. J. Mather 

 REVIEWS

Radioimmunoimaging. Advances and prospects

Van de Wiele C. 1, Revets H. 2, Mertens N. 3

1 Department of Nuclear Medicine University Hospital, Ghent, Belgium
2 Department of Molecular and Cellular Interactions Flanders Interuniversity Institute of Biotec, Brussels, Belgium
3 Department of Molecular Biomedical Research Flanders Interuniversity Institute of Biotec, Ghent, Belgium

The advent of biotechnology has made it possible to overcome the undesired host antiglobulin response evidenced following the injection of rodent antibodies for radioimmunoimaging; initially through the construction of chimeric and CDR-grafted antibodies and more recently through the derivation of completely human antibodies. Available platforms for derivation of completely human antibodies include phage- and ribosome-display techniques and transgenic mice that are deleted in their own antibody genes and reconstituted with large parts of the genes encoding for human antibodies. Additionally, biotechnology has made it possible to tailor affinity, respectively through CDR-walking or chain schuffling, and avidity, respectively through manifold engineering, of antibodies and derivatives. More recent developments include the development of highly stable single domain binders based on the use of a conserved framework region and a highly variable antigen-binding site, using other proteins or molecules that are smaller in size and easier to manufacture than antibodies. Finally, novel technologies have been and are being developed optimizing the concept of pretargeting.

language: English


FULL TEXT  REPRINTS

top of page